Published in Endocr Relat Cancer on June 01, 2003
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet (2005) 1.67
Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer (2010) 1.44
Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene (2009) 1.28
Bioinformatical assay of human gene morbidity. Nucleic Acids Res (2004) 1.23
Systematic evaluation of genetic variation at the androgen receptor locus and risk of prostate cancer in a multiethnic cohort study. Am J Hum Genet (2004) 1.20
Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer. Prostate (2008) 1.12
The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev (2008) 1.03
ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer (2004) 1.00
Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial. J Urol (2010) 0.98
Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev (2010) 0.98
Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle. Prostate (2008) 0.91
Mutations in Fanconi anemia genes and the risk of esophageal cancer. Hum Genet (2011) 0.89
The E-cadherin (CDH1)--160 C/A polymorphism and prostate cancer risk: a meta-analysis. Eur J Hum Genet (2008) 0.86
Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population. Prostate (2010) 0.86
Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet (2004) 0.83
Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors. Virchows Arch (2004) 0.81
Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. Cancer Lett (2008) 0.79
Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. Clin Cancer Res (2010) 0.78
The clinical genetics of prostate cancer. Hered Cancer Clin Pract (2004) 0.75
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell (1994) 7.05
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Genome fingerprinting by simple sequence repeat (SSR)-anchored polymerase chain reaction amplification. Genomics (1994) 6.40
Association of human cyclin E with a periodic G1-S phase protein kinase. Science (1992) 5.98
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (1994) 5.34
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet (1996) 4.38
Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol (1997) 4.36
Emerging infectious diseases and amphibian population declines. Emerg Infect Dis (2000) 4.27
Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med (2001) 3.87
Diagnostic assays and sampling protocols for the detection of Batrachochytrium dendrobatidis. Dis Aquat Organ (2007) 3.78
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res (1997) 3.55
Isolation of an RNA with the properties of haemoglobin messenger. Nature (1969) 3.53
A human RNA polymerase II complex associated with SRB and DNA-repair proteins. Nature (1996) 3.50
A human RNA polymerase II complex containing factors that modify chromatin structure. Mol Cell Biol (1998) 3.45
RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem (1997) 3.26
Mammalian Srb/Mediator complex is targeted by adenovirus E1A protein. Nature (1999) 3.24
Delirium in an intensive care unit: a study of risk factors. Intensive Care Med (2001) 3.23
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res (2000) 3.01
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene (1993) 2.99
Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms. Epidemiology (1999) 2.85
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA (1997) 2.78
BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet (1996) 2.75
Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol (1997) 2.58
Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc Natl Acad Sci U S A (1993) 2.55
Risk factors for suicide completion in major depression: a case-control study of impulsive and aggressive behaviors in men. Am J Psychiatry (2005) 2.54
Alu sequences in the coding regions of mRNA: a source of protein variability. Trends Genet (1994) 2.49
Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet (2004) 2.40
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
NAT, a human complex containing Srb polypeptides that functions as a negative regulator of activated transcription. Mol Cell (1998) 2.33
Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev (1998) 2.30
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate (1983) 2.29
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
PRIMARY CARCINOMA OF THE DUODENUM. Ann Surg (1942) 2.19
Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell (1999) 2.17
In vivo methylation by Escherichia coli K-12 mec+ deoxyribonucleic acid-cytosine methylase protects against in vitro cleavage by the RII restriction endonuclease (R. Eco RII). J Bacteriol (1976) 2.15
The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene (2000) 2.15
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys (1997) 2.10
Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol (1991) 2.07
Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet (2012) 2.06
Standardized nomenclature for Alu repeats. J Mol Evol (1996) 2.00
The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology (2001) 1.99
Ethiopia: between Sub-Saharan Africa and western Eurasia. Ann Hum Genet (2005) 1.98
A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A (1994) 1.95
Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene (1998) 1.94
Comparative study of DNA methylation in three unicellular eucaryotes. J Bacteriol (1978) 1.93
Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest. Mol Cell Biol (1999) 1.91
Complex structure and regulation of the P16 (MTS1) locus. Cancer Res (1995) 1.87
Helminth infestations in immigrant children. Br Med J (1965) 1.87
Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res (1998) 1.83
Cyclin E, a potential prognostic marker for breast cancer. Cancer Res (1994) 1.82
Relationship between 2'-hydroxyls and magnesium binding in the hammerhead RNA domain: a model for ribozyme catalysis. Biochemistry (1991) 1.75
Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet (1996) 1.74
Classification of BRCA1 missense variants of unknown clinical significance. J Med Genet (2005) 1.71
Assignment of the human 3 beta-hydroxysteroid dehydrogenase gene (HSDB3) to the p13 band of chromosome 1. Cytogenet Cell Genet (1989) 1.70
Identification of an overlapping binding domain on Cdc20 for Mad2 and anaphase-promoting complex: model for spindle checkpoint regulation. Mol Cell Biol (2001) 1.70
Genetic structure of the ancestral population of modern humans. J Mol Evol (1998) 1.70
Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians. Am J Hum Genet (1996) 1.68
Reverse transcriptase activity from human embryonal carcinoma cells NTera2D1. EMBO J (1990) 1.68
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab (1994) 1.66
Chromoblastomycosis due to a New Species of Fungus: (First Canadian Case). Can Med Assoc J (1945) 1.66
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med (1982) 1.65
Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene (1999) 1.64
Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences. J Biol Chem (2001) 1.63
Association of sleep-wake habits in older people with changes in output of circadian pacemaker. Lancet (1992) 1.63
Alu RNA secondary structure consists of two independent 7 SL RNA-like folding units. J Biol Chem (1991) 1.60
Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem (1988) 1.60
Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding. Cancer Res (2000) 1.60
Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem (2000) 1.59
Phylogenetic and familial estimates of mitochondrial substitution rates: study of control region mutations in deep-rooting pedigrees. Am J Hum Genet (2001) 1.59
Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol (1999) 1.58
Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene (1996) 1.58
Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer (1996) 1.57
Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs. J Endocrinol (2000) 1.57
Splice-mediated insertion of an Alu sequence inactivates ornithine delta-aminotransferase: a role for Alu elements in human mutation. Proc Natl Acad Sci U S A (1991) 1.56
Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol (2000) 1.54
Immunoglobulin VH gene structure and diversity in Heterodontus, a phylogenetically primitive shark. Proc Natl Acad Sci U S A (1985) 1.54
Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity. Urology (1997) 1.53
The gene for incontinentia pigmenti is assigned to Xq28. Genomics (1989) 1.52
Cyclin E associates with components of the pre-mRNA splicing machinery in mammalian cells. Mol Cell Biol (1998) 1.52
Early carotid endarterectomy after intravenous thrombolysis for acute ischaemic stroke. Eur J Vasc Endovasc Surg (2009) 1.52
Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril (1994) 1.50
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med (1992) 1.50
CORE-SINEs: eukaryotic short interspersed retroposing elements with common sequence motifs. Proc Natl Acad Sci U S A (1999) 1.50
Effect of inhibitors of sodium transport on bile formation in the rabbit. Am J Physiol (1970) 1.49
Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet (1984) 1.49
Thoracic splenosis after blunt trauma: frequency and imaging findings. AJR Am J Roentgenol (1993) 1.48
Modulation of cyclin gene expression by adenovirus E1A in a cell line with E1A-dependent conditional proliferation. J Virol (1994) 1.46